Your browser doesn't support javascript.
loading
Antibody drug conjugates in older patients: State of the art.
Rached, Layal; Geraud, Arthur; Frelaut, Maxime; Ap Thomas, Zoe; Goldschmidt, Vincent; Beraud-Chaulet, Geoffroy; Nagera-Lazarovici, Celine; Danlos, Francois-Xavier; Henon, Clemence; Parisi, Claudia; Gazzah, Anas; Bahleda, Rastilav; Postel Vinay, Sophie; Smolenschi, Cristina; Hollebecque, Antoine; Michot, Jean-Marie; Ribrag, Vincent; Loriot, Yohann; Champiat, Stephane; Ouali, Kaissa; Massard, Christophe; Ponce Aix, Santiago; Bringuier, Michael; Baldini, Capucine.
  • Rached L; Gustave Roussy, Department of Therapeutic Innovation and Early Phase Trials, 94805 Villejuif, France. Electronic address: layalerached@hotmail.com.
  • Geraud A; Gustave Roussy, Department of Medical Oncology , 94805 Villejuif, France. Electronic address: Arthur.GERAUD@gustaveroussy.fr.
  • Frelaut M; Gustave Roussy, Department of Medical Oncology , 94805 Villejuif, France. Electronic address: Maxime.FRELAUT@gustaveroussy.fr.
  • Ap Thomas Z; Gustave Roussy, Department of Medical Oncology , 94805 Villejuif, France. Electronic address: Zoe.AP-THOMAS@gustaveroussy.fr.
  • Goldschmidt V; Gustave Roussy, Department of Therapeutic Innovation and Early Phase Trials, 94805 Villejuif, France. Electronic address: Vincent.GOLDSCHMIDT@gustaveroussy.fr.
  • Beraud-Chaulet G; Gustave Roussy, Department of Medical Oncology , 94805 Villejuif, France. Electronic address: Geoffroy.BERAUD-CHAULET@gustaveroussy.fr.
  • Nagera-Lazarovici C; Gustave Roussy, Department of Medical Oncology , 94805 Villejuif, France. Electronic address: Celine.LAZAROVICI-NAGERA@gustaveroussy.fr.
  • Danlos FX; Gustave Roussy, Department of Therapeutic Innovation and Early Phase Trials, 94805 Villejuif, France. Electronic address: FRANCOIS-XAVIER.DANLOS@gustaveroussy.fr.
  • Henon C; Gustave Roussy, Department of Therapeutic Innovation and Early Phase Trials, 94805 Villejuif, France. Electronic address: Clemence.HENON@gustaveroussy.fr.
  • Parisi C; Gustave Roussy, Department of Therapeutic Innovation and Early Phase Trials, 94805 Villejuif, France. Electronic address: Claudia.PARISI@gustaveroussy.fr.
  • Gazzah A; Gustave Roussy, Department of Therapeutic Innovation and Early Phase Trials, 94805 Villejuif, France. Electronic address: Anas.GAZZAH@gustaveroussy.fr.
  • Bahleda R; Gustave Roussy, Department of Therapeutic Innovation and Early Phase Trials, 94805 Villejuif, France. Electronic address: Rastilav.BAHLEDA@gustaveroussy.fr.
  • Postel Vinay S; Gustave Roussy, Department of Therapeutic Innovation and Early Phase Trials, 94805 Villejuif, France. Electronic address: SOPHIE.POSTEL-VINAY@gustaveroussy.fr.
  • Smolenschi C; Gustave Roussy, Department of Therapeutic Innovation and Early Phase Trials, 94805 Villejuif, France. Electronic address: Cristina.SMOLENSCHI@gustaveroussy.fr.
  • Hollebecque A; Gustave Roussy, Department of Therapeutic Innovation and Early Phase Trials, 94805 Villejuif, France. Electronic address: Antoine.HOLLEBECQUE@gustaveroussy.fr.
  • Michot JM; Gustave Roussy, Department of Therapeutic Innovation and Early Phase Trials, 94805 Villejuif, France. Electronic address: JEAN-MARIE.MICHOT@gustaveroussy.fr.
  • Ribrag V; Gustave Roussy, Department of Therapeutic Innovation and Early Phase Trials, 94805 Villejuif, France. Electronic address: Vincent.RIBRAG@gustaveroussy.fr.
  • Loriot Y; Gustave Roussy, Department of Therapeutic Innovation and Early Phase Trials, 94805 Villejuif, France. Electronic address: Yohann.LORIOT@gustaveroussy.fr.
  • Champiat S; Gustave Roussy, Department of Therapeutic Innovation and Early Phase Trials, 94805 Villejuif, France. Electronic address: Stephane.CHAMPIAT@gustaveroussy.fr.
  • Ouali K; Gustave Roussy, Department of Therapeutic Innovation and Early Phase Trials, 94805 Villejuif, France. Electronic address: Kaissa.OUALI@gustaveroussy.fr.
  • Massard C; Centre Eugène Marquis, Department of Medical Oncology, 35000 Rennes, France. Electronic address: c.massard@rennes.unicancer.fr.
  • Ponce Aix S; Gustave Roussy, Department of Therapeutic Innovation and Early Phase Trials, 94805 Villejuif, France. Electronic address: Santiago.PONCE@gustaveroussy.fr.
  • Bringuier M; Institut Curie, PSL Research University, Department of Medical Oncology and Department of Supportive Care, UCOG Paris Ouest, F-92210 Saint-Cloud, France. Electronic address: michael.bringuier@curie.fr.
  • Baldini C; Gustave Roussy, Department of Therapeutic Innovation and Early Phase Trials, 94805 Villejuif, France. Electronic address: Capucine.BALDINI@gustaveroussy.fr.
Crit Rev Oncol Hematol ; 193: 104212, 2024 Jan.
Article en En | MEDLINE | ID: mdl-38007063
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Inmunoconjugados Límite: Aged / Humans Idioma: En Año: 2024 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Inmunoconjugados Límite: Aged / Humans Idioma: En Año: 2024 Tipo del documento: Article